GlassScriptPhysician profile
Steven K Corse
NPI 1750320073
$8,221.42
in general payments reported to CMS, 2019-2025
51 companies · $22.22 in 2025
The $22.22 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,427 · 2020: $1,083 · 2021: $1,677 · 2022: $1,784 · 2023: $1,616 · 2024: $611 · 2025: $22.22.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,249.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,249.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $987.57 | 2019-2024 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $678.46 | 2019-2024 | |
| Astrazeneca Pharmaceuticals LP | $582.56 | 2019-2024 | Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $564.34 | 2019-2024 | Jardiance, Synjardy, Spiriva Respimat |
| Amgen INC. | $525.10 | 2019-2023 | Repatha, Otezla |
| Abbvie INC. | $516.90 | 2021-2024 | Vraylar |
| Merck Sharp & Dohme LLC | $491.06 | 2020-2023 | Verquvo, Belsomra, Steglatro |
| Lilly USA, LLC | $464.79 | 2019-2024 | Mounjaro, Jardiance, Zepbound |
| Novartis Pharmaceuticals Corporation | $378.09 | 2019-2024 | |
| Otsuka America Pharmaceutical, INC. | $298.99 | 2022-2024 | Rexulti |
| Astellas Pharma US INC | $286.86 | 2019-2023 | Myrbetriq, Veozah |
| Esperion Therapeutics, INC. | $266.53 | 2020-2024 | Nexletol |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $173.41 | 2019-2023 | Xifaxan, Trulance |
| Janssen Pharmaceuticals, INC | $144.82 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $136.87 | 2022-2024 |
Show all 51 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Corse listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.